1. Pyle RL, Abbott J, MacLean H. Pulmonary hypertension and cardiovascular sequelae in 54 dogs. Intern J Appl Res Vet Med. 2004;2(2):99-109.
2. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med. 1999;13(5):440-7.
3. Kellum HB, Stepien RL. Sildenafil citrate therapy in 22 dogs with pulmonary hypertension. J Vet Intern Med. 2007;21(6):1258-64.
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S-12S.
5. Serres F, Chetboul V, Gouni V, Tissier R, Sampedrano CC, Pouchelon JL. Diagnostic value of echo-Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension. J Vet Intern Med. 2007;21(6):1280-9.
6. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler‐derived evidence of pulmonary hypertension: 1992–1996. Journal of Veterinary Internal Medicine. 1999;13(5):440-7.
7. Borgarelli M, Crosara S, Lamb K, Savarino P, La Rosa G, Tarducci A, et al. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med. 2012;26(1):69-75.
8. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-94.
9. Haggstrom J, Duelund Pedersen H, Kvart C. New insights into degenerative mitral valve disease in dogs. Vet Clin North Am Small Anim Pract. 2004;34(5):1209-26, vii-viii.
10. Kellihan HB, Stepien RL. Pulmonary hypertension in canine degenerative mitral valve disease. J Vet Cardiol. 2012;14(1):149-64.
11. Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med. 2009;23(6):1190-6.
12. Kellihan HB, Mackie BA, Stepien RL. NT-proBNP, NT-proANP and cTnI concentrations in dogs with pre-capillary pulmonary hypertension. J Vet Cardiol. 2011;13(3):171-82.
13. Guglielmini C, Civitella C, Diana A, Di Tommaso M, Cipone M, Luciani A. Serum cardiac troponin I concentration in dogs with precapillary and postcapillary pulmonary hypertension. J Vet Intern Med. 2010;24(1):145-52.
14. Oyama MA, Fox PR, Rush JE, Rozanski EA, Lesser M. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc. 2008;232(10):1496-503.
15. Oyama MA, Rush JE, Rozanski EA, Fox PR, Reynolds CA, Gordon SG, et al. Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. J Am Vet Med Assoc. 2009;235(11):1319-25.
16. Angeletti S. Matrix assisted laser desorption time of flight mass spectrometry (MALDI-TOF MS) in clinical microbiology. J Microbiol Methods. 2017;138:20-9.
17. Zhang MH, Xu XH, Wang Y, Linq QX, Bi YT, Miao XJ, et al. A prognostic biomarker for gastric cancer with lymph node metastases. Anat Rec (Hoboken). 2013;296(4):590-4.
18. Pastor MD, Nogal A, Molina-Pinelo S, Melendez R, Salinas A, Gonzalez De la Pena M, et al. Identification of proteomic signatures associated with lung cancer and COPD. J Proteomics. 2013;89:227-37.
19. Gianazza E, Chinello C, Mainini V, Cazzaniga M, Squeo V, Albo G, et al. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors. J Proteomics. 2012;76 Spec No.:125-40.
20. Schwamborn K, Krieg RC, Grosse J, Reulen N, Weiskirchen R, Knuechel R, et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol. 2009;56(6):989-96.
21. Nilsson CL, Berven F, Selheim F, Liu H, Moskal JR, Kroes RA, et al. Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium. J Proteome Res. 2013;12(1):135-50.
22. Teiten MH, Gaigneaux A, Chateauvieux S, Billing AM, Planchon S, Fack F, et al. Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. OMICS. 2012;16(6):289-300.
23. Montgomery H, Rustogi N, Hadjisavvas A, Tanaka K, Kyriacou K, Sutton CW. Proteomic profiling of breast tissue collagens and site-specific characterization of hydroxyproline residues of collagen alpha-1-(I). J Proteome Res. 2012;11(12):5890-902.
24. Bohm D, Keller K, Wehrwein N, Lebrecht A, Schmidt M, Kolbl H, et al. Serum proteome profiling of primary breast cancer indicates a specific biomarker profile. Oncol Rep. 2011;26(5):1051-6.
25. Qin XJ, Ling BX. Proteomic studies in breast cancer (Review). Oncol Lett. 2012;3(4):735-43.
26. Kazmierczak M, Luczak M, Lewandowski K, Handschuh L, Czyz A, Jarmuz M, et al. Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation. Med Oncol. 2013;30(4):725.
27. Pisamai S, Roytrakul S, Phaonakrop N, Jaresitthikunchai J, Suriyaphol G. Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches. PLoS One. 2018;13(7):e0200619.
28. Ploypetch S, Roytrakul S, Jaresitthikunchai J, Phaonakrop N, Krobthong S, Suriyaphol G. Salivary proteomics of canine oral tumors using MALDI-TOF mass spectrometry and LC-tandem mass spectrometry. PLoS One. 2019;14(7):e0219390.
29. Keene BW, Atkins CE, Bonagura JD, Fox PR, Haggstrom J, Fuentes VL, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33(3):1127-40.
30. Kang HS, Lee SC, Park YS, Jeon YE, Lee JH, Jung SY, et al. Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype. BMC Cancer. 2011;11:465.
31. Serafim V, Shah A, Puiu M, Andreescu N, Coricovac D, Nosyrev A, et al. Classification of cancer cell lines using matrix-assisted laser desorption/ionization timeofflight mass spectrometry and statistical analysis. Int J Mol Med. 2017;40(4):1096-104.
32. Boswood A, Dukes-McEwan J, Loureiro J, James RA, Martin M, Stafford-Johnson M, et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract. 2008;49(1):26-32.
33. Tarnow I, Olsen LH, Kvart C, Hoglund K, Moesgaard SG, Kamstrup TS, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J. 2009;180(2):195-201.
34. Wolf J, Gerlach N, Weber K, Klima A, Wess G. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease. J Vet Cardiol. 2012;14(3):399-408.
35. Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract. 2010;51(2):84-96.
36. de Lima GV, Ferreira FDS. N-terminal-pro brain natriuretic peptides in dogs and cats: A technical and clinical review. Vet World. 2017;10(9):1072-82.
37. Langhorn R, Willesen JL. Cardiac troponins in dogs and cats. J Vet Intern Med. 2016;30(1):36-50.
38. Missov ED, De Marco T. Clinical insights on the use of highly sensitive cardiac troponin assays. Clin Chim Acta. 1999;284(2):175-85.
39. Sawada Y, Suda M, Yokoyama H, Kanda T, Sakamaki T, Tanaka S, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. The Journal of biological chemistry. 1997;272(33):20545-54.
40. Chen TT, Klassen TL, Goldman AM, Marini C, Guerrini R, Noebels JL. Novel brain expression of ClC-1 chloride channels and enrichment of CLCN1 variants in epilepsy. Neurology. 2013;80(12):1078-85.
41. Zhang Q, Beltran WA, Mao Z, Li K, Johnson JL, Acland GM, et al. Comparative analysis and expression of CLUL1, a cone photoreceptor-specific gene. Invest Ophthalmol Vis Sci. 2003;44(10):4542-9.
42. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348(6303):730-2.
43. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348(6303):732-5.
44. Kawanabe Y, Nauli SM. Endothelin. Cell Mol Life Sci. 2011;68(2):195-203.
45. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999;91(22):1922-32.
46. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol. 2002;39(3):372-8.
47. Hara T, Takeda TA, Takagishi T, Fukue K, Kambe T, Fukada T. Physiological roles of zinc transporters: molecular and genetic importance in zinc homeostasis. J Physiol Sci. 2017;67(2):283-301.
48. Oresic K, Mueller B, Tortorella D. Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner. Biosci Rep. 2009;29(3):173-81.
49. Katz ML, Farias FH, Sanders DN, Zeng R, Khan S, Johnson GS, et al. A missense mutation in canine CLN6 in an Australian shepherd with neuronal ceroid lipofuscinosis. J Biomed Biotechnol. 2011;2011:198042.
50. Locatelli C, Piras C, Riscazzi G, Alloggio I, Spalla I, Soggiu A, et al. Serum proteomic profiles in CKCS with Mitral valve disease. BMC Vet Res. 2017;13(1):43.
51. Hansson K, Häggström J, Kvart C, Lord P. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound. 2002;43(6):568-75.
52. Cornell CC, Kittleson MD, Della Torre P, Haggstrom J, Lombard CW, Pedersen HD, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med. 2004;18(3):311-21.
53. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. The Journal of biological chemistry. 1951;193(1):265-75.
54. Chaiyarit P, Taweechaisupapong S, Jaresitthikunchai J, Phaonakrop N, Roytrakul S. Comparative evaluation of 5-15-kDa salivary proteins from patients with different oral diseases by MALDI-TOF/TOF mass spectrometry. Clin Oral Investig. 2015;19(3):729-37.
55. Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc. 2016;11(12):2301-19.
56. Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44(D1):D380-4.